Danish Hospitality Stock News

If you’ve been watching H. Lundbeck (CPSE:HLUN B) lately, you might be wondering what’s behind the recent wave of interest in the stock. While there hasn’t been a headline-grabbing event to push shares in a new direction, the stock’s activity could be catching investors’ attention for other reasons. With shares trading right around 45 DKK, even subtle moves can spark curiosity about whether the market is signaling a shift in its view of the Danish pharma specialist. Over the past year, H...

If you are keeping tabs on Novo Nordisk (CPSE:NOVO B), you have likely noticed the surge in attention after this year's European Association for the Study of Diabetes conference. The company released headline-grabbing real-world results for Ozempic, showing that it lowered the risk of heart attack, stroke, and death in older diabetic patients compared to a competitor. Just as importantly, fresh obesity drug and cardiovascular safety data, combined with a sweeping corporate restructuring plan,...

Ørsted (CPSE:ORSTED) just made a move that has everyone in the market talking. The company’s announcement of a massive follow-on equity offering—nearly DKK 60 billion in new shares—signals a clear intent to raise substantial capital. For investors, this kind of capital raising isn’t just about strengthening the balance sheet, it often means management is laying the groundwork for future expansion or tackling emerging risks head-on. When a leading energy player taps the market at this scale,...

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...

Earlier this week, Novo Nordisk announced that the European Medicines Agency approved an updated Rybelsus label to reflect cardiovascular benefits in type 2 diabetes, following the results of the SOUL trial presented at the European Association for the Study of Diabetes 2025 Congress in Vienna. This approval positions Rybelsus as the first oral GLP-1 therapy in the EU with proven cardiovascular benefit, potentially expanding its clinical reach among patients with type 2 diabetes at increased...

Earlier this month, HBM Healthcare Investments announced that its portfolio company Swixx BioPharma signed a multi-regional distribution and services agreement with H. Lundbeck A/S, covering Lundbeck's central nervous system portfolio in South-East Europe, Turkey, and Latin America, as part of a wider transition by Lundbeck to a partnership-based commercial operating model in 27 international markets with Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals. This shift reflects a...

Ørsted A/S recently announced a follow-on equity offering, filing to raise DKK 59.99 billion by issuing 900,816,600 new ordinary shares at DKK 66.6 each. This sizable capital raise through a rights offering structure represents one of the largest share issuances in the company's history and signals a significant move to strengthen its financial position. Next, we'll explore how this capital-raising effort through a large-scale rights offering could impact Ørsted's investment...

Key Insights Netcompany Group's estimated fair value is kr.396 based on 2 Stage Free Cash Flow to Equity Current share...

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

ChemoMetec A/S ( CPH:CHEMM ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...

As European markets experienced a positive week, with the pan-European STOXX Europe 600 Index rising by 1.03% amid expectations of potential U.S. interest rate cuts, investors are increasingly focused on identifying value opportunities in this environment. In such conditions, stocks trading below their estimated intrinsic worth can present appealing prospects for those looking to capitalize on market inefficiencies and potential future growth.

Deciding what to do with NKT stock right now might feel a bit like standing at a crossroads. Maybe you’re eyeing those recent price gains and wondering if there’s still more upside ahead, or perhaps you’re cautious after such a strong run. Over the past week, NKT shares have ticked up by 1.6%, and looking a bit further back, the 30-day return sits at an impressive 5.3%. Year-to-date, the stock has soared by 20.5%. If you zoom out even more, the long-term story gets even more interesting, with...

Deciding what to do with Rockwool stock? You are definitely not alone—it is one of those companies that always sparks debate among investors, especially after a stretch of ups and downs that has put everyone on alert. If you have been watching the chart, you know things have been anything but boring. After a relatively flat week, the share price has taken a 15.3% drop over the past month and sits down 5.1% for the year. Over the past year, Rockwool is off 14.6%, but zoom out to three years...

In the past week, DSV and DB Schenker initiated significant workforce reductions and accelerated cost-cutting efforts to address ongoing volatility in the freight forwarding sector. This development spotlights industry-wide pressures on operational efficiency as global logistics companies adapt to uncertain market conditions. We’ll examine how DSV’s cost-saving measures and restructuring efforts could influence expectations around operational efficiency and future profitability. We've found...

TROPHY GAMES Development A/S ( CPH:TGAMES ) shares have retraced a considerable 28% in the last month, reversing a fair...

If you have been weighing what to do with your A.P. Møller Mærsk stock, or are eyeing it for your portfolio, you are definitely not alone. With global trade dynamics constantly shifting and shipping stocks often acting as a barometer of economic sentiment, the decisions around this Danish giant are anything but dull right now. Let’s cut straight to what has people talking. The mood around Mærsk has shifted over the past year. Shares are up a huge 54.7% over the last twelve months, powering...

H. Lundbeck (CPSE:HLUN B) has recently seen its shares catch a bit of attention, even without a dramatic headline to drive the move. Sometimes, the absence of an obvious trigger can raise just as many questions as a major announcement. It prompts investors to dig a little deeper, asking whether traders are anticipating future news, simply reacting to broader market currents, or reading more subtle signals about Lundbeck’s future prospects. Looking back at the year, there has been a...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

GN Store Nord A/S ( CPH:GN ) shareholders should be happy to see the share price up 22% in the last month. But will...

Vestas Wind Systems (CPSE:VWS) just landed a fresh order that is bound to catch the eye of investors weighing their next move. The company announced a deal with Energiekontor AG in Germany, supplying 13 of its V162-7.2MW turbines and committing to a long-term, 20-year service agreement. While this order itself may not shift the industry's foundations, the combination of scale and a substantial service window signals ongoing appetite for Vestas’ solutions in the key EMEA region. This can be...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

It is hard to get excited after looking at DSV's (CPH:DSV) recent performance, when its stock has declined 17% over the...

Key Insights The considerable ownership by retail investors in Pandora indicates that they collectively have a greater...

Cemat A/S' ( CPH:CEMAT ) robust earnings report didn't manage to move the market for its stock. We did some digging...